SCHEMBL4718352

SCHEMBL4718352

COC(=O)CC1CN(CC(=O)NCCCCNc2ccccn2)CCc2ccccc21

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 10/20 0.45
ITGAV P06756 10/20 0.45
ITGA2B P08514 5/20 0.45
ITGB5 P18084 4/20 0.45
ITGB1 P05556 2/20 0.42
DRD2 P14416 4/20 0.41
HTR2A P28223 1/20 0.41
ADRA1A P35348 3/20 0.39
DRD3 P35462 3/20 0.39
PRMT5 O14744 1/20 0.37
WDR77 Q9BQA1 1/20 0.37
TRPM8 Q7Z2W7 1/20 0.36
MEN1 O00255 1/20 0.36
HTT P42858 1/20 0.36
KMT2A Q03164 1/20 0.36
ALOX12 P18054 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4715705 0.91 ITGB3 (0.55) ITGB3ITGAVITGA2BITGB5ITGB1
SCHEMBL4718120 0.90 ITGB3 (0.54) ITGB3ITGAVITGA2BITGB5ITGB1
SCHEMBL4720020 0.82 ITGB3 (0.46) ITGB3ITGAVITGA2BITGB5ITGB1
SCHEMBL4760965 0.76 NAMPT (0.45) ITGB3ITGAVITGA2BITGB5ITGB1
SCHEMBL4718116 0.76 ITGB3 (0.53) ITGB3ITGAVITGA2BITGB5ITGB1
SCHEMBL4761200 0.75 ITGB3 (0.53) ITGB3ITGAVITGA2BITGB5ITGB1
SCHEMBL6302598 0.74 ITGB3 (0.57) ITGB3ITGAVITGA2BITGB5ITGB1
SCHEMBL4790307 0.73 ITGB3 (0.44) ITGB3ITGAVITGA2BITGB5ITGB1
SCHEMBL4791396 0.73 ITGB3 (0.44) ITGB3ITGAVITGA2BITGB5ITGB1
SCHEMBL6308297 0.72 ITGB3 (0.59) ITGB3ITGAVITGA2BITGB5ITGB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1216230-B1 FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR ANTAGONISTS AMGEN INC (US) 2008-04-23 EP disclosed
US-6514964-B1 Treating diseases, conditions or disorders mediated by integrin receptors, such as vitronectin and fibronectin receptors AMGEN INC. 2003-02-04 US disclosed